Cognitive and disease-modifying effects of 11ß-hydroxysteroid dehydrogenase type 1 inhibition in male Tg2576 mice, a model of Alzheimer's disease

Citation for published version:

Digital Object Identifier (DOI):
10.1210/en.2015-1395

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Peer reviewed version

Published In:
Endocrinology

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
Cognitive and disease-modifying effects of 11β-hydroxysteroid dehydrogenase type 1 inhibition in male Tg2576 mice, a model of Alzheimer’s disease

Karen Sooy¹, June Noble¹, Andrew McBride¹, Margaret Binnie¹, Joyce L.W. Yau¹,², Jonathan R. Seckl¹,², Brian R. Walker¹, Scott P. Webster¹

¹University/BHF Centre for Cardiovascular Science, Queen’s Medical Research Institute, University of Edinburgh, 47 Little France Crescent, Edinburgh EH16 4TJ, UK
²Centre for Cognitive Aging and Cognitive Epidemiology, University of Edinburgh, UK

Abbreviated Title: Effects of 11β-HSD1 inhibition in an AD model

Key terms: 11β-hydroxysteroid dehydrogenase, cognition, enzyme inhibition, Alzheimer’s disease, cortisol

Word count: 5543

Number of figures and tables: 7 Figures, 3 Supplementary Figures, 2 Tables

Corresponding author and person to whom reprint requests should be addressed:

Scott P. Webster

University/BHF Centre for Cardiovascular Science,
Queen’s Medical Research Institute,
University of Edinburgh,
47 Little France Crescent,
Disclosure statement: This work was supported by a Wellcome Trust Seeding Drug Discovery award (to BRW, SPW and JRS). SPW, BRW and JRS are inventors on relevant patents owned by the University of Edinburgh and licensed to pharmaceutical/biotechnology companies. Neither the funder nor the licensee of these patents had any role in study design, analysis or reporting. BRW, JRS and SPW have consulted for pharmaceutical companies developing selective 11β-HSD1 inhibitors.
Chronic exposure to elevated levels of glucocorticoids has been linked to age-related cognitive decline and may play a role in Alzheimer’s disease. In the brain, 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) amplifies intracellular glucocorticoid levels. We show that short term treatment of aged, cognitively impaired C57BL/6 mice with the potent and selective 11β-HSD1 inhibitor UE2316 improves memory, including following intracerebroventricular drug administration to the CNS alone. In the Tg2576 mouse model of Alzheimer’s disease, UE2316 treatment of mice aged 14 months for 4 weeks also decreased the number of beta amyloid (Aβ) plaques in the cerebral cortex, associated with a selective increase in local insulin-degrading enzyme (involved in Aβ breakdown and known to be glucocorticoid-regulated). Chronic treatment of young Tg2576 mice with UE2316 for up to 13 months prevented cognitive decline, but did not prevent Aβ plaque formation. We conclude that reducing glucocorticoid regeneration in the brain improves cognition independently of reduced Aβ plaque pathology, and that 11β-HSD1 inhibitors have potential as cognitive enhancers in age-associated memory impairment and Alzheimer’s dementia.
Introduction

Glucocorticoids have long been recognised to impact on cognitive function, especially with aging (1-3). Older individuals who exhibit learning and memory impairments have elevated glucocorticoid levels that parallel both cognitive deficits and shrinkage of the hippocampus, a key locus for memory formation. The hippocampus expresses a high density of corticosteroid receptors, both the lower affinity glucocorticoid receptor (GR) and the higher affinity mineralocorticoid receptor (MR), and these receptors are also abundant in other neocortical regions associated with cognition (4). Elevated glucocorticoid concentrations in vitro and in vivo promote biochemical, electrophysiological and structural changes in hippocampal neurons, which associate with poorer memory formation (5, 6). Manipulations which maintain low glucocorticoid levels from birth (neonatal programming) or mid-life (adrenalectomy and low dose steroid replacement) prevent the emergence of cognitive deficits with age (7).

Some patients with dementia, including those with Alzheimer’s disease (AD), have elevated circulating cortisol levels, which may contribute to AD pathogenesis (8, 9). It has been postulated that excess glucocorticoids increase levels of amyloid precursor protein (APP) and APP cleaving enzyme (BACE) leading to increased amyloid Aβ formation, reduced Aβ degradation via attenuation of insulin degrading enzyme (IDE) and increased tau expression (10). Other relevant glucocorticoid actions include hyperglycemia/insulin resistance, angiopathic and anti-angiogenic actions, increased excitatory (NMDA) neurotransmission and post-synaptic calcium signaling promoting neurotoxicity, metabolic endangerment of neurons and deleterious alterations in neuroimmune function (11).

Glucocorticoid action via intracellular MR and GR is determined not only by circulating steroid levels but also by target tissue concentrations, modulated by intracellular metabolism by the isozymes of 11β-hydroxysteroid dehydrogenase (11β-HSD) (12). The adult forebrain expresses 11β-HSD type 1, which catalyses conversion of inert 11-keto corticosteroids (cortisone, 11-dehydrocorticosterone) to active cortisol and corticosterone. 11β-HSD1 levels are increased in the aging rodent hippocampus and cortex and correlate with cognitive decline (13). Transgenic mice modestly overexpressing 11β-
HSD1 in the forebrain show premature memory decline with aging, while 11β-HSD1 null mice on
two distinct genetic backgrounds, and even heterozygous null mice (with 50% less enzyme) resist
cognitive decline with aging in a variety of tests (14). This protection associates with loss of the age-
associated rise in intrahippocampal corticosterone levels but without changing plasma corticosterone
levels (13).

Treatment of already aged mice with selective 11β-HSD1 inhibitors improves spatial memory
performance. Effects are rapid, occurring within hours to days (15-17). Moreover, in small
randomized placebo-controlled trials, the non-selective 11β-HSD inhibitor carbenoxolone improved
memory in healthy aging men and in patients with type 2 diabetes (18). Whilst 11β-HSD1 inhibition
improves glucose homeostasis and other metabolic parameters in obesity, metabolic changes were not
correlated with cognitive effects in aged rodents or humans. These results support examination of
selective 11β-HSD1 inhibitors in the treatment of age-related cognitive impairments.

Here we examined a crucial issue, whether selective 11β-HSD1 inhibition alters cognition and
pathology in AD. We used a murine AD model, the well-characterized Tg2576 mouse which bears a
mutated human APP gene. We generated and used UE2316, a novel and selective inhibitor of both
human and rodent 11β-HSD1 with a low nanomolar IC₅₀ value and high penetration into the brain
(19,20).

**Materials and Methods**

**UE2316**

UE2316 ([4-(2-chlorophenyl-4-fluoro-1-piperidinyl][5-(1H-pyrazol-4-yl)-3-thienyl]-methanone) was
synthesized by High Force Ltd, UK according to methods previously described (21). In vitro
screening of UE2316 potency in HEK293 cells stably transfected with hsd11b1 (22) showed a greater
median inhibitory concentration (IC₅₀) than our previously reported compound UE1961 (15, 20).
Inhibition of 11β-HSD1 activity in tissue extracts was quantified as previously described (22). Liver
brain and white adipose tissues were collected and snap frozen on dry ice. Frozen tissue (50-80mg) was homogenized in 700μl of chilled Krebs Buffer and a cleared homogenate prepared by centrifugation at 3500rpm for 5 minutes. The protein concentration of this homogenate was determined by Bradford assay. For the assay, 25μl of 10mM NADPH was added to 250μg of the homogenate in a final volume of 200μl chilled Krebs buffer and incubated at 37°C for 20 minutes. 3H-cortisone (25μl of 200nM) was then added and the assay incubated for a further 15 minutes prior to termination by rapid freezing on dry ice. 3H-cortisone to 3H-cortisol conversion was determined in 50μl of the defrosted reaction by capturing liberated 3H-cortisol on anti-cortisol (HyTest Ltd)-coated scintillation proximity assay beads (protein A-coated YSi, GE Healthcare). The percentage inhibition was determined by measuring the conversion of 3H-cortisone to 3H-cortisol relative to that in tissue from vehicle treated mice.

Animals

All in vivo experiments were performed under a project license issued under the UK Scientific Procedures (Animals) Act, 1986, and with local ethical committee approval. Male C57Bl/6 mice were obtained from Harlan (UK). Male mice were chosen to eliminate the potential effects of gonadal hormonal fluctuations observed in females. Animals were group-housed under controlled lighting (on 07.00-19.00h) and temperature (22°C), with access to food and water ad libitum. Experimental procedures are summarised in Table 1.

For measurement of pharmacodynamic inhibition following oral administration, oral gavages with vehicle (38% PEG, 2% DMSO, 60% saline; Sigma, Poole, UK) or UE2316 dissolved in vehicle were performed in the morning in animals aged 8-10 weeks (n=3 per dose). Animals were sacrificed post dosing (1, 4 and 6 hours) and the tissues retained for analysis of 11β-HSD1 inhibition.

For assessment of pharmacodynamic inhibition following subcutaneous administration, C57Bl/6 mice (8-10 months, Harlan UK) (n=3 per group) were treated with either vehicle (50:50 DMSO: PEG, Sigma) or 10mg/kg/day UE2316 in vehicle via subcutaneously implanted Alzet osmotic minipumps
(model 2004, Charles River, Margate, UK) for 14 days. Animals were sacrificed at this stage and the tissues retained for analysis of 11β-HSD1 inhibition.

To show that the effects of UE2316 were not merely due to any peripheral metabolic actions of 11β-HSD1 inhibition, the agent was administered intracerebroventricularly to aged male C57Bl/6 mice (24 months, obtained from an in-house stock) were treated with either vehicle (artificial CSF; Alzet; Charles River) (n=9) or 100ng/h UE2316 in artificial CSF (n=8) administered via intracerebroventricular (icv) infusion, for 9 days, as previously described (23).

For assessment of the effects of UE2316 on cognition in aging animals, aged male C57Bl/6 mice (22 months, Harlan UK) were treated with either vehicle (n=6), 5mg/kg/day UE2316 (n=8) or 15mg/kg/day UE2316 (n=8) in vehicle (50:50 DMSO: PEG, Sigma) by subcutaneously implanted Alzet osmotic minipumps (model 2004, Charles River, Margate, UK) for 23 days, with body weights monitored at the start and end of the treatment.

For the assessment of the effects of UE2316 in a model of AD, male Tg2576 (Hsiao et al., 1996) and age-matched genetic control (BL6;SJL) littermates were obtained from Taconic Europe (Ry, Denmark). Animals were singly housed due to aggressive behavior. In the short term treatment study, 14 month old mice of each genotype (n=10 per group) were allocated at random to receive either UE2316 (10mg/kg/day) or vehicle (50:50 DMSO: PEG, Sigma) via 2 Alzet osmotic minipumps (model 2004) implanted subcutaneously to provide sufficient volume of drug or vehicle for 29 days. Food intake and body weight were monitored weekly throughout. For the long term study in which UE2316 was administered by incorporation in the diet, 6-7 month old Tg2576 male mice that were screened for eye color, coat color and rd1 homozygosity for the Pde6b<sup>rd1</sup> retinal degeneration mutation by Taconic were fed with control diet (RM1) (n=16) or with RM1 containing 175 ppm UE2316 (for a calculated dosage of 30 mg/kg/day) (n= 32) (Special Diet Services, Broxburn, UK) for up to 57 weeks. Food intake and body weights were monitored weekly throughout the experiment and drug dosages were calculated based on average daily food intake. Each cohort of mice underwent repeated longitudinal cognitive testing.
Behavior

Mice were acclimatized to the behavior room for at least one hour before all procedures in order to minimize stress. All behavioral testing was conducted during the day between 9am and 12pm.

Memory in passive avoidance

Passive avoidance was assessed over 2 days (for aging studies in C57Bl/6 mice on days 13 and 14 after the start of treatment, for the short term UE2316 study in Tg2576 mice on days 27 and 28 and at weeks 15 and 41 in the long term UE2316 Tg2576 study) in a step through light/dark box passive avoidance apparatus (Ugo Basile Comerio, VA, Italy) (13). On the first day, the latency to enter the dark compartment from the light compartment was measured, with the door to the dark compartment opening 30 seconds after the start of the trial. Twenty four hours later, the latency to enter the dark compartment was repeated, which was followed by a mild 0.3mA, 2 second foot-shock in the dark compartment. The mice were then retested 6 hours later for the latency to enter the dark compartment, this time without a foot-shock. The latencies were measured automatically by the device following the opening of the door separating the light and dark compartments with a maximal time allowed of 300 seconds. Mice that did not enter the dark compartment were eliminated from analysis.

Y maze

Y maze testing of spatial hippocampal memory was performed as previously described with a 2 hour inter-trial interval (ITI) on day 10 following the start of treatment in the aged UE2316 study (15). For the UE2316 icv administration study, Y maze testing was performed on day 8 of treatment. The amount of time spent in each arm was measured and analyzed using AnyMaze software (Stoelting, Dublin, Ireland).

Open field

The open field test was performed on day 23 of the short term Tg2576 study and week 38 of the long term Tg2576 study. Mice were placed in an open field (OF) box (60 x60 cm) marked off into 16 equal squares. The outer row of squares adjacent to the walls of the box are considered less anxiogenic than
the inner squares. For a 5 min period, the number of crossings, time, and distance (movement of all
four legs into a new square) into each square was noted. Total movement in the maze reflects general
activity and the relative movement in the inner zone is correlated to the anxiety state of the mouse.

**Spontaneous alternation**

Spontaneous alternation, a test of working hippocampal memory, was tested after 26 days of
treatment in the short term treated Tg2576 mice and after 39 weeks of treatment in the long term diet
study. Mice were placed in a Y maze apparatus consisting of three enclosed black Plexiglas arms (50
cm long, 11 cm wide and 10 cm high), with prominent extramaze visual cues. Mice were allowed to
explore the maze for five minutes after starting in a randomly chosen ‘start’ arm. The order and
number of arm entries by each mouse in the 5 minute test period was recorded. Percentage
spontaneous alternation was calculated using the following formula: % spontaneous alternation=
[number of alternations (which is entries into 3 different arms consecutively)/(number of arms entered
minus 2)] x 100.

**Morris water maze**

Morris water maze testing was performed as previously described on day 14 of the short term study
and week 52 of the long term study (24). For the short term treatment study in Tg2576 mice, mice
who did not swim (i.e. did not engage with the task) during the visible platform test, in which a visual
cue (i.e. stacked Lego blocks) was placed on the submerged platform in the tank and no visuospatial
clues were present (curtains were closed) were eliminated from analysis. The mice undertook 4 trials
per day with a 20 minute inter trial interval and a maximum swim time of 90 seconds per trial for 4
days. Latency, swim speed and the percentage of time spent in each quadrant of the pool were
measured by Watermaze software (Actimetrics, Evanston, IL, USA). In the long term treatment study,
mice were initially assessed after 12 months of treatment for their ability to engage in the visible
platform test. In this instance, mice that were able to find the platform and improve their latencies
after 2 days of 4 x 90 second trials were then tested in the spatial water maze, in which the platform
remained submerged without a visual cue on top and the mice utilised spatial clues located around the
maze (curtains open). Mice were tested in 4 x 90 second trials per day over 6 days. Twenty four
hours after the final spatial water maze trial, the mice were then tested in the 90 second probe test, in
which the hidden platform was removed from the tank and the percentage of time spent swimming in
the target quadrant was measured.

After behavioural testing, mice were sacrificed by cervical dislocation on day 29 of vehicle or
UE2316 treatment in the short term study or after 44 and 57 weeks in the long term study. The brains
were removed and hemisected coronally. One half of the brain was dissected and cortex, hippocampus
and cerebellum were immediately frozen on dry ice and stored at -80°C for further analysis. The other
half was fixed in 4% paraformaldehyde in PBS (4% PFA) (VWR, Lutterworth, UK) and
cryoprotected in 30% sucrose (Sigma) overnight at 4°C before storage at -80°C for
immunohistochemistry.

**Immunohistochemistry**

All immunohistochemistry was performed on free floating 25 µm sections stored at -20°C in
cryoprotectant (50 mM phosphate buffer, 25% glycerol, 25% ethylene glycol, Sigma). Sections were
transferred to a 12 well tissue culture plate with Netwell inserts (VWR) and washed in PBS. Antigen
retrieval was performed by heating the sections in sodium citrate buffer, pH 6.0 (Sigma) at 95°C for
15 minutes, followed by peroxidase treatment (1% H₂O₂ in PBS; Sigma) for 30 minutes to remove
endogenous peroxidase activity, washed and then blocked with the appropriate serum for 1 hour
followed by overnight incubation at 4°C with the antibody of choice. For staining using the 6E10
antibody for visualization of amyloid beta plaques, the sections were blocked using the mouse on
mouse (MOM) Ig blocking reagent (Vector Laboratories, Peterborough, UK) followed by overnight
incubation with a 1:1000 dilution of beta amyloid 1-16 mouse monoclonal antibody (6E10) (Covance,
Cambridge Bioscience, Cambridge, UK). Following washing, sections were incubated with secondary
antibody for 1 hour at room temperature. Staining was visualised using the Vectastain ABC kit and
DAB peroxidase substrate kit (Vector Laboratories). The sections were then mounted on Superfrost
Plus slides (VWR), dehydrated and coverslipped. The number of 6E10 positive plaques per brain area
was counted by an experimenter blinded to the treatment group using a Zeiss Axioskop and the
KS300 imaging program (Zeiss, Eching, Germany). Plaque area, measured using the same program,
was expressed as plaque area divided by the total area of the brain region. Iba-1 antibody was
purchased from Abcam (Cambridge, UK). Goat and rabbit serum were purchased from Sigma.
Biotinylated rabbit anti-goat IgG antibody and biotinylated rabbit anti-sheep IgG antibody were
purchased from Vector Labs.

Western blotting

Protein extracts were prepared from brain areas by homogenization in Krebs buffer containing
protease inhibitor (Roche, Burgess Hill, UK) followed by centrifugation at 3000 RPM for 5 minutes.
Protein concentration of the supernatant was measured using the Bradford Assay (BioRad, Hemel
Hempstead, UK). Proteins were separated by SDS-PAGE using NuPAGE Novex 4-12% bis-tris gels
(Invitrogen, Paisley, UK) and transferred to nitrocellulose membranes (0.2µm pore size; Invitrogen).
Membranes were blocked for 1 hour at room temperature in 5% non-fat dry milk blotting grade
blocker (BioRad) in PBS, pH 7.4, containing 0.1% Tween 20 (PBS-T) and then incubated overnight
with shaking at 4°C with the primary antibody diluted in blocking reagent. This was followed by
incubation at room temperature in the appropriate secondary antibody. IDE, PSD95, ADAM10,
synaptophysin and CD31 antibodies were purchased from Abcam. The anti-BACE 1 N terminus (46-
62) antibody was sourced from Sigma. Mouse beta-tubulin antibody was purchased from Merck-
Millipore (Watford UK). Goat-anti rabbit IgG antibody was obtained from Licor Biosciences UK
(Cambridge UK). Alexa Fluor 680 donkey anti-sheep IgG (H+L) and Alexa Fluor 680 rabbit anti-goat
IgG antibodies were purchased from Invitrogen (Paisley, UK). Proteins were visualized and band
intensities were quantified using the Odyssey Infrared Imaging System (LiCor Biosciences UK,
Cambridge, UK).

Statistical analysis
Data are expressed as mean ± SEM. Groups were compared by ANOVA. When ANOVA was significant post hoc tests were performed as indicated in the Figure legends. Differences were considered significant when p<0.05.

Results

UE2316 inhibits 11β-HSD1 in the brain

We previously reported the discovery and pharmacological effects of the selective 11β-HSD1 inhibitor UE1961, which was based on a thiophene amide scaffold (15). However, this molecule has sub-optimal potency and pharmacokinetic properties for progression to late-stage preclinical development. Further medicinal chemistry optimisation of this compound, replacing the decahydroquinoline and substituted piperidine groups flanking the thiophene core, led to the identification of UE2316 (Figure 1A). UE2316 displays greater potency than UE1961, excellent selectivity and an improved drug metabolism and pharmacokinetic profile for use in in vivo studies (Figure 1B). Pharmacodynamic inhibition of 11β-HSD1 in tissues was confirmed following administration by oral and subcutaneous (SC) routes. Single dose oral administration of UE2316 to C57BL/6 mice induced significant ex vivo inhibition of 11β-HSD1 in the brain for at least 4 hours (Figure 1C), while constant infusion of 10mg/kg/day of UE2316 over 14 days by SC Alzet osmotic minipumps also produced 34.2 ± 8.3 % inhibition of 11β-HSD1 in the brain (data not shown). The results from these studies were in agreement with those from previous studies (19,20). UE2316 was thus chosen to investigate the effects of chronic 11β-HSD1 inhibition on cognitive impairment and AD pathology in mouse models using either SC or oral administration.

UE2316 acts in the brain to improve cognition in aged wild type mice

To assess the effects of UE2316 on memory in cognitively impaired mice, C57BL/6 male mice aged 22 months were randomly assigned to treatment with 0, 5 or 15 mg/kg/day of UE2316 via SC implanted Alzet minipumps for 14 days. In the Y-maze, a non-stressful test of hippocampal-associated spatial memory, there was a significant increase in time spent exploring the novel arm after a 120 min inter-trial interval in mice receiving 15 mg/kg/day UE2316 compared to vehicle-treated
controls (Figure 2A). Cognition was also assessed in the passive avoidance task, which tests emotional and fear associated memories (13). During the retention phase of the passive avoidance test, UE2316 increased latency to enter the dark compartment at both 5 and 15 mg/kg/day compared with vehicle-treated mice, indicating improved memory (of the footshock) (Figure 2B).

To investigate whether brain-specific inhibition of 11β-HSD1 was responsible for these improvements in cognition, we delivered UE2316 directly to the brain of aged (24 month old) C57BL/6 mice at an appropriate concentration via icv administration for 9 days. Post-mortem analysis of whole brain samples revealed 39.9 ± 5.5 % inhibition of 11β-HSD1 was achieved with a 100 ng/h infusion. Vehicle-treated aged controls showed impaired spatial memory in the Y maze (similar times spent in all 3 arms) as previously reported (15). Mice treated with icv UE2316 spent more time exploring the novel arm of the Y-maze than vehicle-treated mice, indicating an improvement in spatial memory after 8 days of treatment (Figure 2C).

**UE2316 improves cognition in a murine model of Alzheimer’s disease**

Following confirmation of the effects of 11β-HSD1 inhibition using UE2316 in age-related cognitive impairment, we examined effects of short-term UE2316 administration in the Tg2576 mouse model of AD. Tg2576 mice carry a transgene with mutations at amino acids 670 and 671 in the human APP gene under the control of the hamster prion promoter, which leads to accumulation of Aβ plaques in the brain from 9-12 months of age with consequent cognitive impairment (25). Singly housed age-matched male mice were separated into 4 groups of 10 mice per group: wild type or Tg2576 mice administered vehicle or UE2316. Mice were treated by 2 SC implanted Alzet minipumps from 14 months of age for 29 days. No treatment-related adverse effects on final body weight, daily food intake or adrenal size were observed. However, as previously reported, Tg2576 mice weighed less than their wild type littermates throughout the study despite consuming more food (Supplementary Figure 1A-B), which may reflect their increase in locomotor activity and hypothalamic dysfunction (26,27).
Tg2576 mice perform poorly in the Y-maze spatial memory test due to retinal degeneration, therefore, fear-associated memory was assessed in the passive avoidance task, which is not dependent on visual acuity. In this test, performed on days 27 and 28 of drug or vehicle administration, UE2316 treatment increased latencies in re-entry to the dark compartment at 6 hours post footshock in both control and Tg2576 mice (Figure 3A), suggesting an improvement in fear associated memory with drug treatment. The effect of UE2316 treatment was particularly pronounced in Tg2576 mice, which may reflect a difference in sensitivity to the electrical shock in this mouse strain. In a separate open field test, no difference was observed in the time spent in the inner zone in either wild type or Tg2576 mice with or without drug (two way ANOVA, treatment effect: p=0.98), suggesting that UE2316 does not affect anxiety (Figure 3B). No difference in speed was observed between either strain, in the presence or absence of drug (two way ANOVA, treatment effect: p=0.94, data not shown).

In spontaneous alternation, a test of working hippocampal memory, Tg2576 mice tended to enter more arms than the control mice (p=0.06), which again may be due to their increased locomotion (data not shown) (26). Treatment with UE2316 led to a trend in increased percentage alternation in both wild type and Tg2576 mice compared to vehicle (two way ANOVA, treatment effect: p=0.06) (Figure 3C).

**UE2316 prevents cognitive decline in a murine model of Alzheimer’s disease**

Effects of long-term UE2316 treatment were examined by administering UE2316 in the diet to 6-7 month old Tg2576 mice over a period of 57 weeks. The mice on the UE2316-supplemented diet maintained an average daily dose of approximately 30 mg/kg/day throughout the experiment and did not exhibit any adverse effects (Supplementary Figure 2A). UE2316-treated mice tended to weigh less than vehicle-treated mice up to 44 weeks (ANOVA, p<0.01) despite eating more food (ANOVA, p<0.001) (Supplementary Figure 2B-C). In contrast to the short-term study, mice were pre-screened for retinal degeneration (RD) and only those which were RD negative were included. Memory was assessed at intervals using passive avoidance, spontaneous alternation and Morris Water Maze tests.
Fear associated memory was assessed using the passive avoidance test after 15 and 41 weeks of treatment. As expected, at 15 weeks, when mice were aged 10-11 months, similarly increased latencies were observed following training in both the vehicle and UE2316-treated groups, consistent with preserved cognitive function at this age (Figure 4A). In contrast, after 41 weeks of treatment, when the mice were aged 16-17 months, vehicle-treated mice exhibited cognitive impairment as demonstrated by lack of prolongation of latency after training, but Tg2576 mice treated with UE2316 maintained an increase in latency to enter the dark compartment 6 hours post shock, indicating that UE2316 prevents an age-associated decline in fear associated memory (Figure 4B). There was an increase in latency for training in vehicle-treated mice, suggesting a impairment in their ability to effectively engage with the task. No difference in anxiety was observed with UE2316 treatment in a separate open field test (two way ANOVA, treatment effect: p=0.25), but Tg2576 mice were less anxious compared to wild type mice (two way ANOVA, genotype effect: p<0.01) (Figure 5A). There was also an increase in locomotion in Tg2576 mice when compared to wild type mice (two way ANOVA, genotype effect: p<0.01), but no effect of treatment (two way ANOVA, treatment effect: p=0.69).

Working memory was assessed at 39 weeks of treatment using the spontaneous alternation test. UE2316 increased spontaneous alternation (Figure 5B), although there was no difference in the total number of arm entries (data not shown).

Spatial memory was assessed in the Morris Water Maze after 52 weeks of treatment (mice aged 18-19 months). Swim speeds were not affected by UE2316 treatment and there was no difference between strains (data not shown). UE2316 reduced the time taken to find the hidden platform across the testing period (Figure 5C), and increased time spent in the target quadrant during the probe test performed 24 hours after the final trial (vehicle: 34.2±3.2%, UE2316: 52.1±5.1%, p=0.02), consistent with improved spatial learning and retention (Supplementary Figure 3A).

Effect of UE2316 on Aβ plaques in the brain
Immunohistochemistry with 6E10 antibody (28), which detects Aβ1-16, was performed on Tg2576 brains to determine whether UE2316 affected the number and volume of Aβ plaques (wild type control brains were not analysed as these mice do not develop amyloid plaques) (Figure 7A).

Short-term 4-week UE2316 treatment decreased Aβ plaque number in the cortex and amygdala but not the hippocampus of 15m old Tg2576 mice (Figure 6A). The total plaque number in the brains of Tg2576 mice was 54% lower in UE2316-treated than vehicle-treated mice. Plaque areas were correspondingly reduced (Figure 6B).

After chronic 44-week treatment with UE2316 (mice aged 17-18 months) there were a similar number of Aβ plaques in the cortex and hippocampus as in mice treated with UE2316 for only 4 weeks (Figure 6C). However, there were fewer Aβ plaques in the brains of the vehicle-treated group from the 44-week study than in the vehicle-treated animals from the 4-week study. In the 44-week study there was no significant effect of UE2316 on number of Aβ plaques.

To explore possible mechanisms mediating the effects of short-term UE2316 treatment on Aβ plaque burden in the cortex we conducted western blot analyses of selected proteins involved in Aβ generation and metabolism, the expression of which are known to be regulated by glucocorticoids (Figure 7B). UE2316 treatment did not modulate BACE protein expression in either WT or Tg2576 mice (Table 2). Nor did UE2316 alter ADAM10, a metalloproteinase possessing α-secretase activity involved in the non-amyloidogenic pathway of APP processing (29) (Table 2). However, UE2316 significantly increased, by 31% and 34% respectively, insulin degrading enzyme (IDE) protein expression in the cortex of both control and Tg2576 mice (Table 2). No difference in IDE expression was found in the brains from mice treated with UE2316 for 44 weeks (IDE to beta-tubulin ratio: vehicle: 0.016 + 0.004 vs UE2316: 0.011 + 0.002; Student’s t-test, p=0.22).

PSD95 and synaptophysin, markers of synaptic density (30,31), were unaffected by UE2316 (Table 2). In addition, microglial density was not increased as evidenced by no change in Iba1 levels (32) (Table 2). CD31 staining was also conducted to probe for potential changes in cerebral vascular
density, as 11β-HSD1 null mice exhibit enhanced angiogenesis (33), but no effect of UE2316 was observed (Table 2).

**Discussion**

We have generated UE2316, which is a potent and selective inhibitor of 11β-HSD1 in mouse brain. UE2316 administered either systemically or directly to the brain induces improvements in memory in cognitively impaired rodents. In aging mice the effects of UE2316 recapitulate those of other selective 11β-HSD1 inhibitors (15, 16) and provide further evidence that short term inhibition of 11β-HSD1 in the brain improves memory impairments associated with aging. Moreover, our data demonstrate that these improvements are associated with inhibition of 11β-HSD1 specifically in the brain since mice treated with icv administration with sub-systemic doses display memory improvements comparable to those observed in mice treated systemically. The effects are evident across a range of behavioral tasks that involve the hippocampus, in contrast with the attenuation of contextual fear-associated memory that we previously reported with UE2316 which is likely mediated in different brain regions (19). It is likely that these short term improvements in memory are due to the effects of reduced intracellular corticosterone in regions of the brain such as the hippocampus, which are sufficient to reverse the memory-impairing effects of glucocorticoids in aged mice (17). Structural changes to the hippocampus, such as synaptic and dendritic atrophy may be reversed by reduced intracellular glucocorticoid levels over a period of hours and weeks respectively, and could be responsible for the short term memory improvements observed in these studies (34,35). However, we also observed significant improvements in memory with long term 11β-HSD1 inhibition which may be mediated by structural hippocampal changes. It should be noted that behavioral testing was only carried out in male mice and the exploration of any potentially sexually dimorphic effects of 11β-HSD1 inhibition will require separate, comparative studies in male and female mice.

There is now substantial evidence from studies in rodents and in humans that reductions in 11β-HSD1 activity in the brain provides beneficial effects on the cognitive decline associated with aging (15, 16,
However, to date no studies have been published that assess the effects on 11β-HSD1 inhibition in rodent models of AD. We found that short term (29 days) treatment of already cognitively-impaired 14-month old Tg2576 mice with UE2316 led to improvements in memory during the passive avoidance task. UE2316 also improved latency in wild type mice but to a lesser extent than in Tg2576 mice. Our data also demonstrate that long term inhibition of 11β-HSD1 in Tg2576 mice maintains cognitive performance with aging since age-matched mice without UE2316 treatment are cognitively impaired in tests performed from 16 months of age onwards. Moreover, cognitive improvement with 11β-HSD1 inhibition is maintained in the presence of significant Alzheimer’s pathology.

In the Tg2576 mouse strain, Aβ plaques have been shown to develop from 9 months of age onwards, associated with impairments in cognitive ability in memory tests from 10-12 months (25). As expected, when we examined the brains of the Tg2576 mice Aβ plaques were observed in the cortex, amygdala and hippocampus. Short term UE2316 treatment substantially decreased Aβ plaque number and area in the cortex and amygdala of Tg2576 mice. In contrast, in a separate cohort of mice from which those with retinal impairment were excluded, we observed less Aβ plaque burden and no statistically significant effects of chronic UE2316 administration. This likely reflects the differences in animals with and without visual impairment. Overall, the results suggest that treatment with UE2316 has a disease-modifying effect on amyloid plaque deposition in Tg2576 mouse brains by impairing plaque accumulation. However, our findings dissociate cognitive improvement from Aβ plaque pathology after chronic treatment, suggesting the mechanism of improved cognition with 11β-HSD1 inhibition is not mediated solely through reduced plaque burden. Whatever the mechanism, the effect on cognition is likely associated with lowered intracellular glucocorticoid levels in the brain, and the consequent altered balance of glucocorticoid and mineralocorticoid receptor action (23).

Additionally, we observed an increase in cortical IDE protein levels with short term UE2316 treatment. This increase may explain, in some part, the reduction in plaque numbers and plaque area in the drug-treated mice, as previous studies have demonstrated that overexpression of IDE or nephrilysin in the neurons of transgenic mice significantly reduced brain amyloid beta levels and
slowed or completely prevented amyloid plaque formation in APP TG mice (36), while IDE null mice have excess cerebral accumulation of Aβ (37). In humans, genome-wide association studies report a higher susceptibility to AD in Finnish patients with polymorphisms of IDE, suggesting that the rate of Aβ degradation may be an important factor in the development of human AD (38). However, the lack of IDE induction with chronic UE2316 administration, in the face of persisting benefits for cognitive function, suggests that other pathways are involved in cognitive protection with 11β-HSD1 inhibition. Alternatively, Tg2576 mice selected for intact vision may be relatively resistant to glucocorticoid effects on IDE and Aβ turnover.

These pre-clinical results support the concept that 11β-HSD1 inhibition may be efficacious for memory impairments not only with aging, but also in AD. A recent phase 2 clinical trial in patients with mild-moderate AD was halted, however, when the selective 11β-HSD1 inhibitor ABT-384 failed to show non-inferiority against donepezil for the primary endpoint of ADAS-Cog score (39). Although a pharmacodynamic study of ABT-384 using stable isotope d4-cortisol tracer has been reported (40), it remains uncertain whether ABT-384 inhibited 11β-HSD1 adequately in brain since: data were presented for only two control subjects without administration of ABT-384; after ABT-384 administration, d3-cortisol levels (generated by 11β-HSD1) (41) were very low in plasma, consistent with systemic enzyme inhibition, and this may account for the undetectable levels of d3-cortisol in CSF; and the maximum CSF concentrations of ABT-384 achieved, which were present for only a short time after dosing, were not high enough to inhibit 11β-HSD1 by more than 10%, according to published potency of the compound. The benefits of 11β-HSD1 inhibition may only be apparent in the treatment of early disease, when the combination of symptomatic cognitive improvement and potential for disease modification we have observed in the mouse model of AD may be most useful.

Acknowledgements
This work was funded primarily by the Wellcome Trust which is gratefully acknowledged. The icv work was funded by the Medical Research Council (G0501596 to JLWY and JRS). We also acknowledge the support of the British Heart Foundation.

References


Webster SP, Seckl JR, Walker BR, Ward P, Pallin TD, Dyke HJ, Perrier TR. (4-Phenyl-piperidin-1-yl)-[5-(1H-pyrazol-4-yl)-thiophen-3-yl]-methanone Compounds and Their Use. Int PCT Application 2011; WO2011033255.


Yau JL, Noble J, Seckl JR. 11β-hydroxysteroid dehydrogenase type 1 deficient prevents memory deficits with aging by switching from glucocorticoid receptor to mineralocorticoid receptor-mediated cognitive control. J Neurosci 2011; 31:4188-4193.


Tables.

Table 1: Treatment table.

Table 2: UE2316 increased IDE protein levels in the cortex of control and Tg2576 mice. Data are mean ± SEM from Western blot densitometry, normalized to beta-tubulin. 2-way ANOVA analysis was performed and the treatment effect of UE2316 is shown. For IDE *p<0.04 for effect of UE2316 within each genotype by post hoc Fisher’s LSD tests.

Figures and Legends.

Figure 1: UE2316 Characteristics. A: Structural comparison of UE1961 and UE2316 B: Potency and selectivity of UE2316. C: Male C57BL6 mice were treated with a single 10 mg/kg oral dose of UE2316 (n=3 animals per time point) and inhibition by scintillation proximity assay was assessed 1, 4 and 6 hours post dosing and expressed as % inhibition compared with values obtained in vehicle-treated mice. (One-way ANOVA, p=0.009; Bonferroni’s post-hoc comparisons, *p<0.05 vs vehicle).

Figure 2: UE2316 improved spatial and fear-associated memory in aged C57Bl6 mice. Aged 22 month-old C57Bl6 mice were treated with 0 (n=6), 5 (n=8) or 15 (n=8) mg/kg/day UE2316 for 23 days via SC implanted osmotic minipumps. A: Spatial memory was assessed by Y maze on day 10 of treatment. The initial 1 minute ITI was performed prior to surgery. Treatment with 15 mg/kg/day UE2316 increased the time spent in the novel arm in the 2 hour ITI compared to vehicle treated animals (*p<0.05 by Student’s t-test with Bonferroni correction), and a trend for improvement was
seen with the 5 mg/kg/day dose. B: Passive avoidance was analyzed on days 13 and 14 of treatment.

Both 5 mg/kg/day (*p=0.02 vs vehicle by Student’s t-test) and 15 mg/kg/day (*p=0.03 by Student’s t-test) UE2316 improved latency in the retention trial compared to the vehicle treated group (by two-way repeated measures ANOVA drug interaction with training vs retention p<0.05). C: Similarly aged C57Bl/6 mice were treated with an infusion of either vehicle (artificial CSF) (n=9) or 100ng/h UE2316 (n=8) via ICV cannulas. Spatial memory was assessed by Y maze on day 9 of treatment. The initial 1 minute ITI was performed prior to surgery. Treatment with UE2316 increased the time spent exploring the novel arm during the 2 hour ITI compared with vehicle-treated controls (**p=0.005 by Student’s t-test).

**Figure 3: UE2316 improved fear-associated behaviour in the passive avoidance test in Tg2576 mice.** Tg2576 and wild type mice (n=10 per group) were treated with vehicle or UE2316 at 10 mg/kg/day by SC Alzet minipump infusion from the age of 14 months for 29 days. A: Tg2576 mice were assessed in the passive avoidance task on days 27 and 28 of drug treatment. The latency to enter the dark compartment was assessed in the training trial (pre) and the retention trial (post). UE2316 increased latency to enter the dark compartment 6 hours post shock (2-way repeated measures ANOVA drug effect p<0.04; **p<0.01 by Student’s t test) to a greater extent in Tg2576 mice (by an increment of 171.6 ± 28.0 seconds compared to 42.6 ± 21.5 seconds in vehicle-treated mice, **p=0.004 by Student’s t-test). B: Open-field was performed after 23 days of treatment in vehicle and UE2316 treated wild type and Tg2576 mice. The percentage of time during the 5 minute trial that was spent in the inner zone of the open field apparatus was measured. There was no significant effect of treatment or genotype. C: Spontaneous alternation was assessed at day 26 of treatment. There was a trend for increased alternation with UE2316 treatment (2-way ANOVA; treatment: p=0.06).

**Figure 4: Long term administration of UE2316 improves cognition in Tg2576 mice.** Tg2576 mice were treated with either control diet (RM1, n=16) or RM1 supplemented with 175 ppm UE2316 for an estimated dose of 30 mg/kg/day (n=32) from the age of 6-7 months for 57 weeks. A: Passive avoidance was analyzed after 15 weeks of treatment with vehicle (n=13) or UE2316 (n=23). Both groups exhibited significantly increased latency to enter the dark compartment in the retention test,
indicating preserved cognitive function but there was no effect of UE2316 (by two-way ANOVA training vs retention effect p<0.001, drug effect p=0.26; by Student’s t-test *p=0.03, ***p=0.0007). B: Passive avoidance was retested after 41 weeks of treatment with vehicle (n=13) or UE2316 (n=23) in chow. UE2316 but not vehicle treated mice demonstrated a significant increase in latency to enter the dark compartment in the retention test (by Student’s t-test **p=0.004).

Figure 5. Behavior of Tg2576 mice following long term administration of UE2316. A: Open field was performed in control (vehicle: n=5, UE2316: n=5) and Tg2576 mice (vehicle: n=13, UE2316: n=23) after 38 weeks of treatment with either normal chow or diet containing UE2316. The Tg2576 mice spent more time in the inner zone than their wild type counterparts; however, there was no effect of drug administration (by two-way ANOVA, *p<0.05). B: Spontaneous alternation was assessed in Tg2576 mice after 39 weeks of vehicle (n=13) or UE2316 treatment (n=23). UE2316-treated mice exhibited a significant increase in percent alternation compared to control mice (by Student’s t-test *p=0.04). C: The spatial Morris Water Maze test was performed after 52 weeks of treatment. Mice that were able to find the platform in a visible platform test were tested in their ability to find the submerged platform using spatial cues located around the testing room. UE2316 treated mice (n=9) exhibited significant decreases in latency to find the hidden platform across the testing period compared to vehicle treated animals (n=6) (2-way repeated measures ANOVA, drug effect p=0.02 and interaction of drug with time p<0.01; by Student’s t-tests *p<0.05 at days 3, 5 and 6).

Figure 6: Effect of short- and long-term UE2316 administration on amyloid plaque burden in Tg2576 mice. A: Short term plaque number. 6E10 positive amyloid plaques were counted in at least 5 non-sequential sections per mouse treated for 29 days with vehicle or UE2316 (n=10 per treatment) via SC minipumps using the KS300 imaging program and the total number of positive plaques was expressed per area of the brain. UE2316 had no effect on plaque number in the hippocampus but decreased 6E10 staining in the cortices (Student’s t-test, **p=0.002), amygdala (Student’s t-test, *p=0.05) and whole brain (Student’s t-test, *p=0.01) in comparison to vehicle. B: Short term plaque area. Total plaque area of short term (29 day) treated mice was measured using the KS300 imaging program and was expressed as plaque area divided by the total area of the brain region in question.
The total plaque area in the cortex was decreased by UE2316 in comparison to vehicle (Student’s t-test, ***p=0.0001). C: Long term plaque number. 6E10 positive amyloid plaques were counted in at least 5 non-sequential sections per mouse treated for 44 weeks with vehicle or UE2316 (n=5 per treatment) in the diet using the KS300 imaging program and the total number of positive plaques was expressed per area of the brain. UE2316 had no statistically significant effect on plaque number in the hippocampus or cortex in comparison to vehicle.

**Figure 7:** Effects on brain pathology in Tg2576 mice treated with UE2316. A: Representative brain sections from Tg2576 mouse showing amyloid plaques in brain regions stained with 6E10 antibody. (a) cortex, vehicle treated (b) cortex, UE2316-treated (c) amygdala, vehicle-treated (d) amygdala, UE2316-treated (e) hippocampus, vehicle-treated (f) hippocampus, UE2316-treated. B: Representative western blot of cortex protein (30µg/sample) from 29 day treated mice. Quantitation was performed using the Odyssey Infrared imaging system and adjusted for beta-tubulin. IDE levels were increased in UE2316 treated cortices compared to vehicle treated tissues in both wild type and Tg2576 animals (see Table 1).

**Supplementary Data.**

**Supplementary Figure 1:** Effects of short-term (29 day) treatment with UE2316 in wild type and Tg2576 mice on food intake and body weight. Wild-type and Tg2576 mice were treated via subcutaneously implanted Alzet minipumps with either vehicle or 10 mg/kg/day UE2316 for 29 days (n=10 per treatment). A: Body weights were measured weekly in all mice. There was no effect of UE2316 on body weight although the Tg2576 mice weighed less than the controls (two-way repeated measures ANOVA, genotype effect p<0.001 and interaction with time p=0.001). B: Food was weighed weekly in all mice. Food intake was averaged as grams of food consumed/day. Tg2576 mice consumed more food but there was no effect of UE2316 (two-way repeated measures ANOVA genotype effect p=0.004).
Supplementary Figure 2: Effects on food intake and body weight with long-term inhibition of 11β-HSD1 in Tg2576 mice by UE2316 supplemented diet. A: Estimated daily drug dosage was calculated weekly by measuring the food intake and comparing with body weight. The dose of UE2316 remained constant throughout the experiment. B: Individually housed mice treated with either control diet (RM1; n=16) or RM1 diet supplemented with 175 ppm UE2316 (RM1 + UE2316; n=32) were weighed weekly. 5 animals per group were culled after 45 weeks and the remainder continued until 57 weeks. By repeated measures ANOVA, there was an interaction of drug treatment with time only before 45 weeks (p<0.01) with UE2316 treated animals tending to be lighter in the early weeks of the study. C: Food intake was measured weekly in both groups and was averaged as grams of food/day. Food intake was higher in mice fed diet supplemented with UE2316 in the first few weeks of the study (by repeated measures ANOVA, drug interaction with time p<0.001; by Student’s t-test *p<0.05 at week 10).

Supplementary Figure 3: Effects on behavior and brain pathology in Tg2576 mice treated with UE2316. The water maze probe test was performed 24 hours after the final spatial water maze trial. UE2316-treated Tg2576 mice (n=9) spent significantly more time exploring the target quadrant of the water maze than the vehicle treated mice (n=6) (*p=0.02).